INSIDER
Medicare plans to restrict access to controversial Alzheimer’s drug Aduhelm to patients in clinical trials
Read full article: Medicare plans to restrict access to controversial Alzheimer’s drug Aduhelm to patients in clinical trialsThe Centers for Medicare and Medicaid (CMS) are drastically cutting down on who can get Aduhelm, limiting it only to people enrolled in clinical trials.